22 Works
Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.
Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.
Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.
Additional file 1 of Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)
Benjamin Rolland, Caroline Lions, Vincent Di Beo, Patrizia Carrieri, Nicolas Authier, Tangui Barré, Jessica Delorme, Philippe Mathurin, François Bailly, Camelia Protopopescu & Fabienne Marcellin
Additional file 1. STROBE Statement—Checklist of items that should be included in reports of cohort studies.
Additional file 1 of Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study)
Benjamin Rolland, Caroline Lions, Vincent Di Beo, Patrizia Carrieri, Nicolas Authier, Tangui Barré, Jessica Delorme, Philippe Mathurin, François Bailly, Camelia Protopopescu & Fabienne Marcellin
Additional file 1. STROBE Statement—Checklist of items that should be included in reports of cohort studies.
Additional file 1 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 1: Table S1. Characteristics and outcome of patients presenting with cefoxitin-susceptible-ESBL-PE infections admitted in the ICU during the study period.
Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.
Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.
Additional file 1 of Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Jean Chastre, Bruno François, Marc Bourgeois, Apostolos Komnos, Ricard Ferrer, Galia Rahav, Nicolas De Schryver, Alain Lepape, Iftihar Koksal, Charles-Edouard Luyt, Miguel Sánchez-García, Antoni Torres, Philippe Eggimann, Despoina Koulenti, Thomas L. Holland, Omar Ali, Kathryn Shoemaker, Pin Ren, Julien Sauser, Alexey Ruzin, David E. Tabor, Ahmad Akhgar, Yuling Wu, Yu Jiang, Antonio DiGiandomenico … & Hasan S. Jafri
Additional file 1: Supplementary Methods, Results, Tables and Figures.
Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.
Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.
Rehabilitation professionals’ views on individual peer support interventions for assisting stroke survivors with reintegration into the community: a qualitative study
Sara Corbin, Eleonore Damiolini, Anne Termoz, Laure Huchon, Gilles Rode, Anne-Marie Schott & Julie Haesebaert
We aimed to explore stroke rehabilitation professionals’ understanding and representations of peer support; the benefits they anticipated for patients; and the levers and barriers they perceived to implement the intervention in their practice. This qualitative study comprised four focus groups with 21 rehabilitation professionals and four semi-structured interviews. It was held in a French hospital. Interpretation was guided by the Consolidated Framework for Implementation Research. Although professionals had poor knowledge on peer support, they identified...
Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.
Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.
Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.
Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.
Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.
Additional file 1 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 1: Table S1. Characteristics and outcome of patients presenting with cefoxitin-susceptible-ESBL-PE infections admitted in the ICU during the study period.
Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.
Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.
Additional file 1 of Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Jean Chastre, Bruno François, Marc Bourgeois, Apostolos Komnos, Ricard Ferrer, Galia Rahav, Nicolas De Schryver, Alain Lepape, Iftihar Koksal, Charles-Edouard Luyt, Miguel Sánchez-García, Antoni Torres, Philippe Eggimann, Despoina Koulenti, Thomas L. Holland, Omar Ali, Kathryn Shoemaker, Pin Ren, Julien Sauser, Alexey Ruzin, David E. Tabor, Ahmad Akhgar, Yuling Wu, Yu Jiang, Antonio DiGiandomenico … & Hasan S. Jafri
Additional file 1: Supplementary Methods, Results, Tables and Figures.
Rehabilitation professionals’ views on individual peer support interventions for assisting stroke survivors with reintegration into the community: a qualitative study
Sara Corbin, Eleonore Damiolini, Anne Termoz, Laure Huchon, Gilles Rode, Anne-Marie Schott & Julie Haesebaert
We aimed to explore stroke rehabilitation professionals’ understanding and representations of peer support; the benefits they anticipated for patients; and the levers and barriers they perceived to implement the intervention in their practice. This qualitative study comprised four focus groups with 21 rehabilitation professionals and four semi-structured interviews. It was held in a French hospital. Interpretation was guided by the Consolidated Framework for Implementation Research. Although professionals had poor knowledge on peer support, they identified...
Affiliations
-
Hospices Civils de Lyon22
-
Hôpital de la Croix-Rousse18
-
University of Lyon System18
-
Claude Bernard University Lyon 118
-
Inserm18
-
Centre Hospitalier Lyon Sud16
-
Centre Hospitalier Universitaire d'Angers16
-
Biometry and Evolutionary Biology Laboratory16
-
Air Liquide (France)16
-
University of Angers16